Casirivimab and Imdevimab

Casirivimab and Imdevimab together are a COVID-19 neutralizing antibody treatment infusion. What does that mean? 

Let’s break it down: When you become infected with COVID-19, your body makes antibodies to fight off the virus. Think about antibodies like little blood warriors. When you’re sick, your body produces lots of soldiers to defend against foreign invaders. 

It takes time for your body to make enough antibodies to successfully fend off the virus. That’s where casirivimab and imdevimab can help. Casirivimab and imdevimab contain man-made antibodies, similar to the ones found in patients who have recovered from COVID-19. 

These man-made antibodies may help fend off the virus, giving your body some extra time to make its own warriors. Receiving the drug may help COVID-19 symptoms improve sooner, making a hospital visit less likely. 

Requirements for treatment

Supplies are very limited. It will not be possible for everyone who becomes sick with COVID-19 to receive this infusion at this time. 

Casirivimab and imdevimab are NOT available at our emergency departments or clinics. 

Because supplies are so limited, to receive this infusion, you must meet at least one of the following requirements:

  • Age 65 or older
  • A body mass index (BMI) of 35 or greater
  • Have a compromised immune system, or some other high-risk condition that could cause you to become very sick from COVID-19

And have tested positive for COVID-19 at a Nebraska Medicine location.

To be tested for COVID-19 through Nebraska Medicine, please follow these instructions

How it works

Casirivimab and imdevimab are intravenous (IV) infusions. They go directly into your blood through a small needle inserted into your arm. 

Nebraska Medicine offers the treatment at one of our infusion centers. 

The appointment takes three to four hours. You only need to receive this infusion one time. 

Questions and answers

How will I know if I'm selected to receive casirivimab and imdevimab?

Due to limited supplies, to receive casirivimab and imdevimab from Nebraska Medicine, you must have tested positive for COVID-19 at a Nebraska Medicine location. 

Doctors will decide who receives treatment based on a variety of risk factors. As the supply of medication increases, the requirements for receiving casirivimab and imdevimab will be reconsidered. 

You will receive a phone call from a Nebraska Medicine representative if you are selected. 

Do casirivimab and imdevimab have the COVID-19 virus in it?

No, casirivimab and imdevimab do not contain any COVID-19 virus. 

Are casirivimab and imdevimab still being studied?

Yes, they are investigational medicines. They are still being studied in clinical trials, so there’s a lot scientists don’t know about their benefits and risks. 

Are casirivimab and imdevimab approved by the U.S. Food and Drug Administration (FDA)?

The FDA has authorized casirivimab and imdevimab for emergency use during the COVID-19 pandemic. They have not yet been fully approved by the FDA. The emergency use authorization can be terminated or revoked at any time. 

How soon does it start working?

Everyone’s body reacts differently, so there’s no way to know for sure. In clinical trials, people who took casirivimab and imdevimab began to see their symptoms improve after about six days. People who received a placebo infusion improved after about eight days. 

Is it the same as a vaccine?

No, casirivimab and imdevimab are not vaccines. Vaccines help your body make its own antibodies. Casirivimab and imdevimab give your body man-made antibodies. These man-made antibodies may give your body more time to naturally produce its own antibodies.

Related Links:

Have questions? We're here to help.

Call for more information